Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Astrazeneca Plc ADR (NQ: AZN )

65.63 +1.37 (+2.13%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Astrazeneca Plc ADR

< Previous 1 2 3 4 5 6 7 8 9
...
59 60 Next >
Elon Musk Breaks Ranks With GOP By Praising Genetic Engineering Tech That Helped Fight COVID-19: 'Digital Medicine With Incredible Potential'
Elon Musk has come off as a flagbearer of the mRNA technology, which is seen holding out a lot of promise by scientists. 
Via Benzinga
Mitigating Muscle Loss Becoming More Vital, Global Cancer Cachexia Market Projected to Reach $3.3 Billion in 2024
EQNX::TICKER_START (OTCPK:MUSLF),(CSE:MUSL),(NYSE:MRK),(NYSE:PFE),(NASDAQ:MRNA),(NASDAQ:AZN) EQNX::TICKER_END 
Via FinancialNewsMedia
AstraZeneca Pulls Plug On Vaxzevria COVID-19 Vaccine Amid Surplus of Updated Vaccines
It is worth noting that AstraZeneca has previously conceded in court documents that Vaxzevria can induce side effects such as blood clots and low blood platelet counts. 
Via Benzinga
Exposures COVID-19
Will Earnings Cheer Continue To Buoy Markets? Apple, Amazon, Pfizer, Coinbase Lead Flurry Of Q1 Reports This Week
With the earnings season now halfway through, the percentage of S&P 500 companies reporting positive earnings surprises and the magnitude of earnings surprises were above their 10-year averages. 
Via Benzinga
Topics Stocks
Exposures US Equities
Mitigating Muscle Loss Becoming More Vital, Global Cancer Cachexia Market Projected to Reach $3.3 Billion in 2024
From FN Media Group LLC
Via GlobeNewswire
7 Stocks to Buy Before the Next ‘Great Reset’ Begins in 2024
These are seven stocks to buy to fortify your portfolio and brace for potential economic upheaval before the next "Great Reset." 
Via InvestorPlace
Actinium Pharmaceuticals (NYSE: ATNM): A Prime Target in a Wave of Radiopharmaceutical Mergers and Acquisitions
Via AB Newswire
Cellectis Announces Completion of the Additional Equity Investment by AstraZeneca
From Cellectis Inc.
Via GlobeNewswire
Top Analyst Reports For AstraZeneca, Qualcomm & FedEx
Today's Research Daily features new research reports on 16 major stocks, including AstraZeneca PLC (AZN), QUALCOMM Incorporated (QCOM) and FedEx Corporation (FDX​​​​​​​). 
Via Talk Markets
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
CALQUENCE combination regimen demonstrated statistically significant and clinically meaningful improvement in progression-free survival in 1st-line mantle cell lymphoma in ECHO Phase III trial
From AstraZeneca
Via Business Wire
Federal Trade Commission Targets 'Junk Patent Listings' For Diabetes, Weight Loss, Asthma Drugs From Companies Like Novo Nordisk, AstraZeneca
The FTC intensifies efforts against pharmaceutical patent listings, disputing junk patents for diabetes, weight loss, asthma, and COPD medications. This initiative combats tactics hindering generic... 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
AstraZeneca unveils latest research across key respiratory and immune-mediated diseases at ATS 2024 showcasing strength of its broad pipeline and portfolio
From AstraZeneca
Via Business Wire
AstraZeneca Admits Its COVID-19 Vaccine May Cause Blood Clotting Side Effect In Very Rare Case, But Causal Mechanism Unknown
Discover the latest on AstraZeneca's Covid vaccine lawsuit. Allegations of serious side effects, including fatalities and brain injuries, spark legal battles. Learn about the controversy and potential... 
Via Benzinga
Topics Lawsuit
Exposures COVID-19 Financial Legal
Double Good News For AstraZeneca's Breast Cancer Drugs
Results from AstraZeneca's Enhertu trial vs. chemotherapy in HR-positive, HER2-low metastatic breast cancer. 
Via Benzinga
ENHERTU® (fam-trastuzumab deruxtecan-nxki) improved PFS in HER2-low and ultralow
From AstraZeneca
Via Business Wire
Pharma Stock Roundup: Merck, Sanofi, AstraZeneca, Novartis' Q1 Results, Pipeline & Regulatory Updates
The first-quarter 2024 earnings season picked up pace this week, with Merck, Sanofi, Novartis, and AstraZeneca announcing their first-quarter results. Three of the four companies beat estimates for... 
Via Talk Markets
Stock Market Rebounds; Tesla, Microsoft, Google, Meta, Chipotle, GE In Focus: Weekly Review
Microsoft, Tesla, Google, GE and Chipotle were earnings winners. Meta was a notable loser. 
Via Investor's Business Daily
Top 4 Health Care Stocks That May Plunge This Month
Via Benzinga
Why Caterpillar Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
AstraZeneca Plc (AZN) Q1 2024 Earnings Call Transcript
AZN earnings call for the period ending March 31, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Stocks Drop, Tech Tumbles With Meta's Weak Outlook, Q1 Stagflation Fears; Gold Miners Advance: What's Driving Markets Thursday?
Wall Street suffers a double blow in Thursday’s session, as softer-than-expected revenue forecasts from Meta Platforms Inc. (NASDAQ:META) are being compounded by weaker-than-expected economic growth... 
Via Benzinga
Topics Economy
Exposures Interest Rates
Sanofi Reports Strong Earnings, Joins Kirby, Sonic Automotive, Union Pacific And Other Big Stocks Moving Higher On Thursday
Via Benzinga
AstraZeneca Posts Bumper Earnings On Strong Sales From Cancer Drugs, Sticks To Annual Guidance
AstraZeneca reports Q1 sales of $12.68 billion, up 17% Y/Y. Despite missing adjusted EPADS, oncology sees a 26% surge, driven by Tagrisso and Imfinzi. Cardiovascular sales up 20%. R&D up 18%. Fiscal... 
Via Benzinga
Why Big Pharma Is Following Novartis' Lead In A $25 Billion Market
The radiopharmaceuticals space could be worth up to $25 billion, according to one estimate. 
Via Investor's Business Daily
AZN Stock Earnings: AstraZeneca Misses EPS, Beats Revenue for Q1 2024
AZN stock results show that AstraZeneca missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024. 
Via InvestorPlace
AstraZeneca, Sanofi Jump On First-Quarter Earnings; Bristol Myers Lags
AstraZeneca soundly topped analyst views while Sanofi narrowed its losses. Both stocks surged in early trade. 
Via Investor's Business Daily
Q1 2024 results
From AstraZeneca
Via Business Wire
US Stocks Brace For Negative Start Amid Tech Earnings Disappointments, Caution Ahead Of Data: 'Worst Of This Two-Week Decline Is Behind Us,' Says Analyst
The back-and-forth motion in the market continues, with the index futures pointing to a lower opening on Thursday. Meta Platforms, Inc.’s (NASDAQ:META) 
Via Benzinga
3 Underappreciated Pharmaceutical Stocks to Buy Before They Surge
These are the undervalued pharmaceutical stocks to buy as they have a deep clinical pipeline which will driven earnings and cash flow growth. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 8 9
...
59 60 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.